Drug intelligence / Profile preview

BJT-574

Development stage: Preclinical
Lead developer: BlueJay Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

BJT-574 is an orally bioavailable small-molecule hepatitis B surface antigen (HBsAg) inhibitor being developed for the treatment of chronic hepatitis B virus (HBV) infection. It was initially developed by Novartis and is now being advanced by Bluejay Therapeutics, which is positioning it as a liver-targeted HBV transcript inhibitor designed to efficiently reduce HBsAg production from HBV-infected hepatocytes, with the goal of restoring antiviral immunity and contributing to a functional cure, potentially in combination with other HBV-directed agents such as anti-HBsAg monoclonal antibodies.[3][4][5]

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on BJT-574.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJT-574.

Explore the full profile